Effects of acute administration of mazindol on brain energy metabolism in adult mice.
Gonçalves, Cinara Ludvig; Scaini, Giselli; Rezin, Gislaine Tezza; Jeremias, Isabela Casagrande; Bez, Gisele Daiane; Daufenbach, Juliana Felipe; Gomes, Lara Mezari; Ferreira, Gabriela Kozuchovski; Zugno, Alexandra Ioppi; Streck, Emilio Luiz.
; 26(3): 146-54, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25142190
Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.
Pharmacokinetics study of mazindol in plasma, oral fluid, and urine of volunteers.
Mazindol: a risk factor for pulmonary arterial hypertension?
ADHD Medication in the Longer Term.
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults.
A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice.
Efficacy of psychostimulant drugs for amphetamine abuse or dependence.
Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment.
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.